Recombinant Rat Reticulon-4 (Rtn4), partial

Code CSB-YP862389RA
MSDS
Size Pls inquire
Source Yeast
Have Questions? Leave a Message or Start an on-line Chat
Code CSB-EP862389RA
MSDS
Size Pls inquire
Source E.coli
Have Questions? Leave a Message or Start an on-line Chat
Code CSB-EP862389RA-B
MSDS
Size Pls inquire
Source E.coli
Conjugate Avi-tag Biotinylated
E. coli biotin ligase (BirA) is highly specific in covalently attaching biotin to the 15 amino acid AviTag peptide. This recombinant protein was biotinylated in vivo by AviTag-BirA technology, which method is BriA catalyzes amide linkage between the biotin and the specific lysine of the AviTag.
Have Questions? Leave a Message or Start an on-line Chat
Code CSB-BP862389RA
MSDS
Size Pls inquire
Source Baculovirus
Have Questions? Leave a Message or Start an on-line Chat
Code CSB-MP862389RA
MSDS
Size Pls inquire
Source Mammalian cell
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Purity
>85% (SDS-PAGE)
Target Names
Rtn4
Uniprot No.
Alternative Names
Rtn4; NogoReticulon-4; Foocen; Glut4 vesicle 20 kDa protein; Neurite outgrowth inhibitor; Nogo protein
Species
Rattus norvegicus (Rat)
Protein Length
Partial
Tag Info
Tag type will be determined during the manufacturing process.
The tag type will be determined during production process. If you have specified tag type, please tell us and we will develop the specified tag preferentially.
Form
Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
Buffer before Lyophilization
Tris/PBS-based buffer, 6% Trehalose, pH 8.0
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20℃/-80℃. Our default final concentration of glycerol is 50%. Customers could use it as reference.
Troubleshooting and FAQs
Storage Condition
Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Shelf Life
The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
Lead Time
Delivery time may differ from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.
Notes
Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet
Please contact us to get it.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Required to induce the formation and stabilization of endoplasmic reticulum (ER) tubules. They regulate membrane morphogenesis in the ER by promoting tubular ER production. They influence nuclear envelope expansion, nuclear pore complex formation and proper localization of inner nuclear membrane proteins. However each isoform have specific functions mainly depending on their tissue expression specificities.; Developmental neurite growth regulatory factor with a role as a negative regulator of axon-axon adhesion and growth, and as a facilitator of neurite branching. Regulates neurite fasciculation, branching and extension in the developing nervous system. Involved in down-regulation of growth, stabilization of wiring and restriction of plasticity in the adult CNS. Regulates the radial migration of cortical neurons via an RTN4R-LINGO1 containing receptor complex. Acts as a negative regulator of central nervous system angiogenesis. Inhibits spreading, migration and sprouting of primary brain microvascular endothelial cells (MVECs). Also induces the retraction of MVECs lamellipodia and filopodia in a ROCK pathway-dependent manner.; Mainly function in endothelial cells and vascular smooth muscle cells, is also involved in immune system regulation. Modulator of vascular remodeling, promotes the migration of endothelial cells but inhibits the migration of vascular smooth muscle cells. Regulates endothelial sphingolipid biosynthesis with direct effects on vascular function and blood pressure. Inhibits serine palmitoyltransferase, SPTLC1, the rate-limiting enzyme of the novo sphingolipid biosynthetic pathway, thereby controlling production of endothelial sphingosine-1-phosphate (S1P). Required to promote macrophage homing and functions such as cytokine/chemokine gene expression involved in angiogenesis, arteriogenesis and tissue repair. Mediates ICAM1 induced transendothelial migration of leukocytes such as monocytes and neutrophils and acute inflammation. Necessary for immune responses triggered by nucleic acid sensing TLRs, such as TLR9, is required for proper TLR9 location to endolysosomes. Also involved in immune response to LPS. Plays a role in liver regeneration through the modulation of hepatocytes proliferation. Reduces the anti-apoptotic activity of Bcl-xl and Bcl-2. This is likely consecutive to their change in subcellular location, from the mitochondria to the endoplasmic reticulum, after binding and sequestration. With isoform C, inhibits BACE1 activity and amyloid precursor protein processing.; Regulates cardiomyocyte apoptosis upon hypoxic conditions. With isoform B, inhibits BACE1 activity and amyloid precursor protein processing.
Gene References into Functions
  1. Nogo-A signaling in the adult nervous system modulates the spine actin cytoskeleton within minutes to control structural plasticity at dendritic spines of CA3 pyramidal neurons. Acute Nogo-A loss-of-function transiently increases F-actin stability and results in an increase in dendritic spine density and length. Nogo-A acutely restricts AMPAR insertion and membrane potential amplitude at hippocampal synaptic sites. PMID: 26748478
  2. Nogo-A shRNA interference can knockdown Nogo gene expression and upregulate GAP-43 to promote the functional recovery of spinal cord injury in rats. This finding may advance progress toward assisting the regeneration of injured neurons through the use of Nogo-A shRNA. PMID: 27035338
  3. The observation of upregulated Nogo-A/NgR in lesion sites in the neonatal cortex freeze-lesion model suggest that the effects of the perturbed Nogo-A are a key feature during the development and/or the progression of cortical malformation. PMID: 26987715
  4. Data suggest that adipose-derived stem cells (ADSCs) transplantation could promote the recovery of neurological functions, partly by inhibiting the expression of neurite outgrowth inhibitor-A (Nogo-A) in middle cerebral artery occlusion (MCAO) brain. PMID: 26728376
  5. the Nogo/NgR signal might be involved in multiple processes in various inflammation-associated CNS diseases. PMID: 26472924
  6. Study shows the expression pattern of Nogo-A in the ventral mesencephalon of adult rats by immunohistochemistry PMID: 25554426
  7. Results suggest that the integrin signaling pathway is regulated by Amino-Nogo, which inhibits optic nerve regeneration and functional recovery. PMID: 25612921
  8. a novel mechanism that functionally couples cAMP signaling with the proteolytic turnover of NOGO-A, positively impacting on neurite outgrowth in mammalian brain. PMID: 25331889
  9. the antibodies that bind to aa 634-668 and aa 1026-1055 of NogoA may have stimulatory effects on axon growth and branching PMID: 24533107
  10. Nogo-A deficiency leads to cognitive deficit in processing of the reference frames. Such a deficit may be the result of neuro-developmental alterations resulting from Nogo-A deficiency. PMID: 24211256
  11. Our results identify Nogo-A as an influential molecular modulator of synaptic plasticity and as a regulator for learning of skilled movements in the motor cortex. PMID: 24966370
  12. A somatotopic side switch anatomically and functionally in the projection of adult corticospinal neurons is induced by the destruction of one sensorimotor cortex and the neutralization of the central nervous system growth inhibitory protein Nogo-A. PMID: 24355710
  13. the association of RhoGDIalpha with TROY contributed to TROY-dependent RhoA activation and neurite outgrowth inhibition after Nogo-66 stimulation. PMID: 24129566
  14. Synthetic microRNA-mediated downregulation of Nogo-A in transgenic rats reveals its role as regulator of synaptic plasticity and cognitive function. PMID: 23576723
  15. There is a direct correlation between the expression of Nogo-A and Nogo-C mRNA in human frontal cortex and the presence of a CAA insert (and TATC deletion) in the 3' UTR of the Nogo gene. PMID: 17022955
  16. Interacting with peroxiredoxin 2 (Prdx2), amino-Nogo-A reduces reactive oxygen species (ROS) generation and extracellular signal-regulated kinase phosphorylation to exert neuroprotective effects. PMID: 22261619
  17. Current results suggest a novel role for Nogo-A in maintaining a restricted branching phenotype in oligodendrocytes process outgrowth, which is a key step towards myelin membrane sheet formation and myelination. PMID: 21624429
  18. The results of this study suggested that transcription and translation of Nogo-A in hippocampal neurons is regulated by a signaling through NgR1. PMID: 21985178
  19. Nogo-A was expressed in the retinal ganglion cells and upregulated after the induction of ocular hypertension PMID: 21643729
  20. These data suggest that PKB is involved in the inhibition of neurite outgrowth by Nogo-A in PC12 cells. PMID: 21862940
  21. A reticulon protein is identified as one out of a selected number of caspase targets during apoptosis and as a novel substrate for Cdk1 and 2. PMID: 18072206
  22. Nogo-A and NgR are expressed in the retinal and visual cortex during development. PMID: 21418929
  23. knockdown of Nogo-A may serve as a novel therapeutic strategy to prevent the loss of cardiomyocytes following ischemic/hypoxic injury. PMID: 21420413
  24. a novel mechanism by which PIR-B-mediated regulation is achieved differentially but competitively via MHCI and Nogo in cells of the immune system PMID: 21636572
  25. Reticulon RTN4 (NogoA) is broadly expressed in oligodendrocytes and neurons and suppresses long-term potentiation in a Nogo receptor-1 (NgR1)-dependent manner. PMID: 20844138
  26. Zuogui pill and Yougui pill can prevent axonal injury and promote the axonal regeneration by increasing the expression of NGF and reduce the expression of Nogo A and its receptor. PMID: 20473744
  27. Nogo-A is a developmental neurite growth regulatory factor with a role as a negative regulator of axon-axon adhesion and growth, and as a facilitator of neurite branching PMID: 20573699
  28. Nogo-A was expressed on the surface of neural stem cells (NSCs). PMID: 20374087
  29. The expression of Nogo-A increases while oligodendrocyte precursor cell viability decreases after oxygen and glucose deprivation. PMID: 18095590
  30. neuronal Nogo-A is an important intermediate in neurite growth dynamics and its expression is regulated by signals related to axonal injury and regeneration PMID: 19901030
  31. Pincher-dependent macroendocytosis leads to the formation of Nogo-A signaling endosomes, which act both within growth cones and after retrograde transport in the cell body to negatively regulate the neuronal growth program. PMID: 20083601
  32. Expression and localization of Nogo-A mRNA in rat nerve tissue PMID: 12133526
  33. During development from postnatal day 21 Nogo-A is expressed in association with tubulin and myelin basic protein in mature oligodendrocytes in the spinal cord. PMID: 12377379
  34. Data show that axonal regeneration and functional recovery are impaired after a sciatic nerve crush, using regulated transgenic expression of Nogo-A in peripheral nerve Schwann cells. PMID: 12379801
  35. Nogo-A is present in the nucleus, pericaryon, and membrane of neurons. Its close relationship with chromatin and mRNA-rich structures suggests possible involvement in transcription/translation. PMID: 12577319
  36. expression of the Nogo-66 domain by otherwise permissive myelinating cells is sufficient to hinder axonal reextension after trauma PMID: 12837628
  37. Three different Nogo-A active sites were discovered involved in inhibition of fibroblast spreading, restricting neurite outgrowth and collapsing growth cones PMID: 12843238
  38. Nogo-A interacts in trans with axonal Caspr at CNS paranodes, an interaction that may have a role in modulating axon-glial junction architecture and possibly K(+)-channel localization during development. PMID: 14592966
  39. Following injury to the spinal cord, Nogo-A protein mRNA is upregulated around the lesion and Nogo-A protein is strongly expressed in injured dorsal column fibers and their sprouts which entered the lesion site. PMID: 14697671
  40. Distribution of Nogo A in rat neuronal cell bodies and axons of adult rat gastrointestinal tract points to a hitherto unsuspected role for Nogo A in enteric neuronal physiology. PMID: 15306002
  41. Nogo-A, -B, and -C share a 180-amino acid C-terminal domain with two highly conserved hydrophobic stretches that could form a channel or transporter in the ER and/or on the cell surface PMID: 15640160
  42. Nogo-R mRNA was expressed in the olfactory bulb, hippocampus, tentia tecta, some amygdala nuclei, cerebral cortex, some thalamic nuclei, medial habenular, whereas could not detect it in the other regions. PMID: 15661372
  43. Layer V pyramidal neurons of the S1 barrel cortex exhibit a pattern of cell size-dependent intraneuronal Nogo-A expression. PMID: 16260091
  44. Neuronal expression of Nogo-A mRNA and protein during neurite outgrowth in the developing rat olfactory system. PMID: 16262653
  45. increases in Nogo-A and SPRR1A in several important brain regions suggest that the injured brain is capable of expressing proteins promoting axonal outgrowth following traumatic brain injury PMID: 16321384
  46. These results demonstrate that antibodies against a CNS cell surface protein(NOGO-A) reach their antigen through the CSF and can induce its downregulation. PMID: 16697217
  47. The specific decrease of Nogo mRNA levels in hippocampus and possibly cortex cerebri may relate to age-dependent decline of brain plasticity. PMID: 16738487
  48. Our data suggest that Nogo-A is involved in secondary axonal degeneration and that inhibition of Nogo-A can reduce neuronal damage in the thalamus after distal MCAO. PMID: 17382469
  49. The cellular localisation and expression pattern of the NOGO receptor and Nogo-A in the mammalian nervous system are reported. PMID: 17428512
  50. In the ipsilateral hippocampus, the expression of Nogo-A relative to MSF suggests that this protein may partially control aberrant synaptic reorganization during epileptogenesis. PMID: 17439704

Show More

Hide All

Subcellular Location
[Isoform A]: Endoplasmic reticulum membrane; Multi-pass membrane protein. Cell membrane; Multi-pass membrane protein; Cytoplasmic side.; [Isoform B]: Endoplasmic reticulum membrane; Multi-pass membrane protein. Cell membrane; Multi-pass membrane protein; Extracellular side. Cell junction.; [Isoform C]: Endoplasmic reticulum membrane; Multi-pass membrane protein.
Tissue Specificity
Isoforms A, B and C are present in optic nerve, spinal cord and cerebral cortex. Isoforms A and B are present in dorsal root ganglion, sciatic nerve and PC12 cells after longer exposure. Isoforms B and C are detected in kidney, cartilage, skin, lung and s
Database Links
icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1